Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems
JAMA Internal Medicine · 16.11.2026
DOI: 10.1001/jamainternmed.2026.5774 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, online erschienen am 16.11.2026. Verfasst von Shaimaa Elshafie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
Autor:innen und Institutionen
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
- Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut.
- Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
- Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
Zitieren
APA
Elshafie, S., Chen, R. Z., Taherifard, E., Ramachandran, R., Ross, J. S., & Wallach, J. D. (2026). Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.5774
Vancouver
Elshafie S, Chen RZ, Taherifard E, Ramachandran R, Ross JS, Wallach JD. Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.5774
BibTeX
@article{Elshafie2026,
author = {Elshafie, Shaimaa and Chen, Rou-Zhen and Taherifard, Erfan and Ramachandran, Reshma and Ross, Joseph S and Wallach, Joshua D},
title = {Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems},
journal = {JAMA Internal Medicine},
year = {2026},
doi = {10.1001/jamainternmed.2026.5774}
}
EUVIMED